Nov. 21 at 4:27 PM
$ACAC My personal approach with Мainz Biomed is simple — I treat it as a high-conviction long-term spec with a tiny allocation, a multi-year horizon and a clear thesis built on a ~
$20B+ TAM, strong CRC and pancreatic data and a ~67% gross margin platform sitting at microcap levels, and if management can convert this science into
$10M,
$50M or
$100M+ revenue over time, even a small position today has the potential to make a very real difference in my long-term equity curve 🚀